bioRxiv Science⌕ Search

Biology subjects

Ngugi, C.

Publications and source records attributed to Ngugi, C..

2 recordsLinked to original sources

Molecular characterization of chikungunya viruses associated with outbreaks in Kenya from 2017 to 2020

In 2014, Chikungunya virus (CHIKV) infections were reported in Kilifi, Kenya, followed by a major outbreak in Mandera County in 2016. Since then, information regarding subsequent outbreaks in Kenya has been scarce. A study on the burden and etiologies of acute febrile illnesses (AFI) in Kenya reported an increase in CHIKV cases in Mombasa between December 2017 and December 2019. In January and February 2020, another outbreak of CHIKV occurred in Dadaab-Hagadera. These recurrent outbreaks necessitated the establishment of the molecular characteristics and phylogenetic differences of the CHIKVs collected from Mombasa and Dadaab-Hagadera. The challenge of distinguishing chikungunya fever (CHIKF) from other AFIs also underscored the importance of describing predictors of laboratory-confirmed CHIKV cases versus other AFIs. Sequences generated revealed that the Indian Ocean Lineage (IOL) was associated with sporadic CHIKV outbreaks in Kenya from 2017 to 2020. When sequences were compared to the 2014 Kilifi outbreak, key mutations associated with increased CHIKV viral fitness in mosquito vectors, including E1-K211E and E2-V264A, were observed in both Dadaab-Hagadera and Mombasa samples. Time-informed Bayesian phylogenetic analysis demonstrated clear geographic structuring, with Mombasa sequences forming tightly clustered clades and Dadaab-Hagadera sequences grouping separately, indicating sustained local transmission at both sites. However, some conserved amino acid substitutions were shared between the two locations, including nsP1-A104V and E2-I94V, suggesting circulation of closely related lineages. When the association of symptoms to positive CHIKV cases was compared to other AFI symptoms, sore muscles, headache, and convulsions were significantly more common in CHIKV cases. In contrast, diarrhea was considerably less frequent in CHIKV patients. Cough, skin rash, conjunctivitis, and vomiting were not significantly associated with CHIKV infection. In regions with limited access to point-of-care diagnostics, identifying clinical symptoms that are likely to be strongly associated with CHIKV infection can be important in the differential diagnosis from other AFIs, facilitating reliable patient screening and improving diagnostic accuracy, particularly during outbreaks when timely identification of CHIKV is critical. Continuous molecular surveillance of circulating CHIKV genotypes is important as the mutations identified in these CHIKV strains continuously accumulate and may have a significant impact on control strategies.

molecular biology↗

Outcomes of Isoniazid Preventive Therapy among people living with HIV in Kenya: A retrospective study of routine health care data

Introduction Isoniazid preventive therapy (IPT) taken by People Living with HIV (PLHIV) protects against tuberculosis (TB). Despite its recommendation, there is scarcity of data on the uptake of IPT among PLHIV and factors associated with treatment outcomes. We aimed to determine the proportion of PLHIV initiated on IPT, IPT treatment outcomes and screening for TB during and after IPT.Methods A retrospective cohort study of a representative sample of PLHIV initiated on IPT between July 2015 and June 2018 in Kenya. We abstracted information on socio-demographic, TB screening practices, IPT initiation, follow up, and outcomes from health facilities’ patient record cards, IPT cards and IPT registers. Further, we assessed baseline characteristics as potential correlates of developing TB during and after treatment and IPT completion using multivariable logistic regression.Results We enrolled 138,442 PLHIV into ART during the study period and initiated 95,431 (68.9%) into IPT. Abstracted files for 4708 patients initiated on IPT, out of which 3891(82.6%) had IPT treatment outcomes documented, 4356(92.5%) had ever been screened for TB at every clinic visit and 4,243(90.1%) had documentation of TB screening on the IPT tool before IPT initiation. 3712(95.4%) of patients with documented IPT treatment outcomes completed their treatment. 42(0.89%) of the abstracted patients developed active TB, 16(38.1%) during and 26(61.9%) after completing IPT. Follow up for TB at 6-month post-IPT completion was done for 2729(73.5%) of patients with IPT treatment outcomes. Sex, Viral load suppression and clinic type were associated with TB development (p<0.05). Levels 4, 5, FBO, and private facilities and IPT prescription practices were associated with IPT completion (p<0.05).Conclusion Two-thirds of PLHIV were initiated on IPT, with a high completion rate. TB screening practices were better during IPT than after completion. Development of TB during and after IPT emphasises need for keen follow up.View Full Text

scientific communication and education↗